文献速递其他结缔组织病

肌炎特异性自身抗体在特发性炎症性肌病相关间质性肺病中的作用及管理:一项系统综述

The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review.
PubMed 文献 · Semin Arthritis Rheum · 2022-08-31

该系统综述纳入112篇论文,评估肌炎特异性自身抗体(MSA)与特发性炎症性肌病(IIM)患者间质性肺病(ILD)表现的关系,并比较不同免疫抑制方案的治疗结局。抗ARS和抗MDA5抗体阳性患者ILD发生率持续高于其他MSA组;抗ARS阳性者慢性ILD比例更高,抗MDA5阳性者快速进展型ILD比例更高。小样本量、缺乏头对头试验和非随机设计妨碍了就免疫抑制管理得出有意义的结论。

要点

  • 抗ARS和抗MDA5抗体阳性患者ILD发生率持续高于其他MSA组。
  • 抗ARS阳性者慢性ILD更多,抗MDA5阳性者快速进展型ILD更多。
  • 小样本量、缺乏头对头试验和非随机设计妨碍了免疫抑制管理结论的得出。

核心结论

  • 某些MSA与ILD表现存在明确关系。
  • IIM相关ILD的标准治疗是糖皮质激素,对有快速进展型ILD风险或已出现快速进展型ILD的患者以及难治性病例加用其他免疫抑制剂。
  • 免疫抑制剂应优先用于已被研究并显示有效的MSA人群。

研究设计与样本

  • 系统综述,纳入112篇论文,评估MSA与IIM患者ILD表现的关系并比较不同免疫抑制方案的治疗结局。

主要发现

  • 抗氨基酰tRNA合成酶(anti-ARS)和抗黑色素瘤分化相关基因5(anti-MDA5)抗体阳性患者ILD发生率持续高于其他MSA组。
  • 抗ARS阳性患者慢性ILD比例更高,抗MDA5阳性患者快速进展型ILD(RP-ILD)比例更高。
  • 抗ARS和抗MDA5阳性患者ILD最常见的HRCT模式分别为非特异性间质性肺炎(NSIP)和不可分类型。
  • 抗转录中介因子1-γ(anti-TIF1-γ)、抗Mi-2、抗核基质蛋白2(anti-NXP-2)和抗3-羟基-3-甲基戊二酰辅酶A还原酶(anti-HMGCR)抗体与ILD风险降低相关。

临床怎么用

  • IIM相关ILD的标准治疗是糖皮质激素,对有快速进展型ILD风险或已出现快速进展型ILD的患者以及难治性病例加用其他免疫抑制剂。
  • 免疫抑制剂应优先用于已被研究并显示有效的MSA人群。

局限性

  • 小样本量妨碍了就免疫抑制管理得出有意义的结论。
  • 缺乏头对头试验妨碍了就免疫抑制管理得出有意义的结论。
  • 非随机设计妨碍了就免疫抑制管理得出有意义的结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the role of myositis-specific autoantibodies (MSAs) in interstitial lung disease (ILD), management of idiopathic inflammatory myopathies (IIM) associated ILD, and if there is a role for MSA specific management of ILD. METHODS: A systematic review was performed examining how MSAs relate to ILD manifestations in IIM patients and comparing treatment outcomes with varying immunosuppressive regimens. RESULTS: 112 papers were included in this analysis. Patients with anti-aminoacyl tRNA synthetase (anti-ARS) and anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibodies had consistently higher rates of ILD than other MSA groups. Anti-ARS positive patients had higher rates of chronic ILD whereas anti-MDA5 positive patients had higher rates of rapidly progressive ILD (RP-ILD). The most common high-resolution computed tomography (HRCT) patterns for ILD in anti-ARS and anti-MDA5 positive patients were nonspecific interstitial pneumonia (NSIP) and unclassifiable respectively. Anti-transcription intermediary factor 1-gamma (anti-TIF1-γ), anti-Mi-2, anti-nuclear matrix protein 2 (anti-NXP-2), and anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR) antibodies were associated with a decreased risk of ILD. Small sample sizes, a lack of head-to-head trials, and non-randomized designs prevented drawing meaningful conclusions with respect to immunosuppressive management. CONCLUSION: Clear relationships exist with regards to the ILD manifestations of certain MSAs. Standard therapy for IIM associated ILD (IIM-ILD) is glucocorticoids with the addition of others immunosuppressives in patients with or at risk of RP-ILD as well as in refractory cases. Immunosuppressives should be preferentially used in MSA populations in which they have been studied and shown to be efficacious.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Teel A, Lu J, Park J, et al. The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review. Semin Arthritis Rheum. 2022. PMID: 36116345. doi:10.1016/j.semarthrit.2022.152088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。